Literature DB >> 8838017

Development in vitro of mouse oocytes from primordial follicles.

J J Eppig1, M J O'Brien.   

Abstract

The objective of these studies was to achieve complete oocyte development in vitro beginning with the oocytes in the primordial follicles of newborn mouse ovaries. A two-step strategy was developed: first the ovaries of newborn mice were grown in organ culture for 8 days, and then the developing oocyte-granulosa cell complexes were isolated from the organ-cultured ovaries and cultured for an additional 14 days. The oocytes of primordial follicles are approximately 4190 microns3 in volume (20 microns in diameter), and this volume increased by approximately 53,810 microns3 to a final size of 58,000 microns3--a 13.8-fold increase--during the 8 days of organ culture. In the first experiment the oocyte-granulosa cell complexes were grown in control medium or in medium supplemented with FSH (0.5 ng/ml), epidermal growth factor (EGF; 1.0 ng/ml), or EGF plus FSH. Only 50-60% of the complexes cultured in control medium or in medium supplemented with FSH were recovered at the end of the 14-day culture period. In contrast, more than 90% of the complexes cultured in medium supplemented with EGF were recovered. The median size of the oocytes grown in control medium was 176,800 microns3 (69-microns diameter), while the median size of those grown in medium supplemented with EGF was slightly smaller (136,400-microns3 volume; 63-microns diameter), due to the survival of more smaller-size oocytes in EGF-containing medium. Thirty percent of the oocytes recovered after development in FSH-containing medium were competent to undergo germinal vesicle breakdown (GVB). In the second set of experiments, oocyte-granulosa cell complexes isolated from organ-cultured ovaries were cultured in medium supplemented with either 0.5 or 5.0 ng/ml FSH or with these same concentrations of FSH plus 1.0 ng/ml EGF. Again, increased oocyte recovery was observed in the groups cultured with EGF. There was no difference among the groups in the percentage of the oocytes that acquired competence to undergo GVB (32%) or in the percentage of GVB oocytes that produced a polar body, thus indicating progression of meiosis to metaphase II (22%). When the mature oocytes were inseminated, 21% underwent fertilization and cleavage to the 2-cell stage in the groups without EGF during oocyte development, while 42% underwent fertilization and cleavage to the 2-cell stage in the groups cultured with EGF. Less than 2% of the 2-cell-stage embryos developed to the blastocyst stage in any of the groups. One hundred and ninety 2-cell-stage embryos were transferred to the oviducts of pseudopregnant females; two females produced one pup each; one was living and the other had apparently died recently. The results reported here clearly show that complete development of oocytes in vitro from the primordial follicle stage is possible and establish the framework for further studies using oocytes from laboratory animals as model systems for the development of oocytes from humans as well as from animals of agricultural and zoological importance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8838017     DOI: 10.1095/biolreprod54.1.197

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  166 in total

Review 1.  Fertility preservation for children treated for cancer (1): scientific advances and research dilemmas.

Authors:  R Grundy; R G Gosden; M Hewitt; V Larcher; A Leiper; H A Spoudeas; D Walker; W H Wallace
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

2.  Efficient isolation and long-term viability of bovine small preantral follicles in vitro.

Authors:  T Itoh; H Hoshi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-04       Impact factor: 2.416

3.  The mammalian oocyte orchestrates the rate of ovarian follicular development.

Authors:  John J Eppig; Karen Wigglesworth; Frank L Pendola
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

4.  Resumption of meiosis-I tissue to enucleated preovulatory oocytes: a preliminary report.

Authors:  Chia-Woei Wang; Ying-Ming Lai; Ping-Ru Chan; Shang-Gwo Horng; Chia-Lin Chang; Chun-Kai Chen; Hsien-Ming Wu; Hong-Yuan Huang; Hsin-Shih Wang; Yung-Kuei Soong
Journal:  J Assist Reprod Genet       Date:  2002-10       Impact factor: 3.412

5.  In vitro follicle growth under non-attachment conditions and decreased FSH levels reduces Lhcgr expression in cumulus cells and promotes oocyte developmental competence.

Authors:  Flor Sánchez; Sergio Romero; Firas K Albuz; Johan Smitz
Journal:  J Assist Reprod Genet       Date:  2011-12-22       Impact factor: 3.412

6.  Embryonic fibroblasts enable the culture of primary ovarian follicles within alginate hydrogels.

Authors:  David Tagler; Tao Tu; Rachel M Smith; Nicholas R Anderson; Candace M Tingen; Teresa K Woodruff; Lonnie D Shea
Journal:  Tissue Eng Part A       Date:  2012-03-02       Impact factor: 3.845

7.  Isolated primate primordial follicles require a rigid physical environment to survive and grow in vitro.

Authors:  J E Hornick; F E Duncan; L D Shea; T K Woodruff
Journal:  Hum Reprod       Date:  2012-03-28       Impact factor: 6.918

8.  NPHP4 is necessary for normal photoreceptor ribbon synapse maintenance and outer segment formation, and for sperm development.

Authors:  Jungyeon Won; Caralina Marín de Evsikova; Richard S Smith; Wanda L Hicks; Malia M Edwards; Chantal Longo-Guess; Tiansen Li; Jürgen K Naggert; Patsy M Nishina
Journal:  Hum Mol Genet       Date:  2010-11-15       Impact factor: 6.150

9.  Targeted suppression of Has2 mRNA in mouse cumulus cell-oocyte complexes by adenovirus-mediated short-hairpin RNA expression.

Authors:  Koji Sugiura; You-Qiang Su; John J Eppig
Journal:  Mol Reprod Dev       Date:  2009-06       Impact factor: 2.609

10.  Suppression of Notch signaling in the neonatal mouse ovary decreases primordial follicle formation.

Authors:  Daniel J Trombly; Teresa K Woodruff; Kelly E Mayo
Journal:  Endocrinology       Date:  2008-09-25       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.